DADC
PCRX icon

D.A. Davidson & Co’s Pacira BioSciences PCRX Stock Holding History

D.A. Davidson & Co’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-13,592
Closed -$620K – 1137
2017
Q4 		$620K Buy
13,592
+864
+7% +$34.2K 0.01% 600
2017
Q3 		$477K Sell
12,728
-133
-1% -$5.35K 0.01% 691
2017
Q2 		$613K Buy
12,861
+1,507
+13% +$69.9K 0.01% 570
2017
Q1 		$517K Buy
11,354
+593
+6% +$25.6K 0.01% 596
2016
Q4 		$347K Sell
10,761
-1,084
-9% -$36.2K 0.01% 780
2016
Q3 		$405K Buy
11,845
+416
+4% +$16.3K 0.01% 701
2016
Q2 		$385K Buy
11,429
+1,696
+17% +$83.4K 0.01% 632
2016
Q1 		$514K Buy
9,733
+1,709
+21% +$100K 0.02% 520
2015
Q4 		$615K Buy
8,024
+7,610
+1,838% +$431K 0.02% 487
2015
Q3 		$16K Buy
414
+114
+38% +$6.98K ﹤0.01% 1732
2015
Q2 		$21K Buy
+300
New +$23.6K ﹤0.01% 1697
2014
Q1 		– Sell
-100
Closed -$5K – 2169
2013
Q4 		$5K Buy
+100
New +$5.26K ﹤0.01% 1862

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

D.A. Davidson & Co's PCRX Position: Q1 2018 in Review

D.A. Davidson & Co sold out of Pacira BioSciences (PCRX) in Q1 2018, closing a stake of 13,592 shares — an estimated $620K sold.

D.A. Davidson & Co first reported a position in PCRX in Q4 2013 and held it in 12 quarters. The position peaked at $620K in Q4 2017. 168 funds tracked by Wall St. Rank hold PCRX as of Q1 2018.

  • D.A. Davidson & Co reported no remaining Pacira BioSciences position as of Q1 2018 after selling out during the quarter.
  • D.A. Davidson & Co sold 13,592 Pacira BioSciences shares in Q1 2018, an estimated $620K.
  • D.A. Davidson & Co first reported a position in Pacira BioSciences in Q4 2013 and held it in 12 quarters.
  • D.A. Davidson & Co's Pacira BioSciences position peaked at $620K in Q4 2017.
  • 168 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2018.

Based on D.A. Davidson & Co's 13F filing for Q1 2018, filed 4 May 2018.